{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=39",
    "query": {
      "intervention": "Drug A (Blinded Drug)",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 972,
    "total_pages": 98,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T23:42:13.458Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04455802",
      "title": "Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neonatal Opioid Withdrawal Syndrome"
      ],
      "interventions": [
        {
          "name": "Buprenorphine or Placebo",
          "type": "DRUG"
        },
        {
          "name": "Morphine or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-10-01",
      "completion_date": "2021-05-17",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04455802"
    },
    {
      "nct_id": "NCT00756236",
      "title": "A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Myocardial Ischemia"
      ],
      "interventions": [
        {
          "name": "Metoprolol",
          "type": "DRUG"
        },
        {
          "name": "Esmolol",
          "type": "DRUG"
        },
        {
          "name": "P-Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-10",
      "completion_date": "2015-09-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-31",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00756236"
    },
    {
      "nct_id": "NCT05987163",
      "title": "Study to Evaluate the Safety and Effectiveness of GP0116",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin Manifestations"
      ],
      "interventions": [
        {
          "name": "GP0116",
          "type": "DEVICE"
        },
        {
          "name": "Active Comparator: FDA approved dermal filler device (RHA 3)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2023-04-12",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 18,
      "location_summary": "Santa Monica, California • Vista, California • Westport, Connecticut + 14 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Westport",
          "state": "Connecticut"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05987163"
    },
    {
      "nct_id": "NCT00870311",
      "title": "Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Lithium Carbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 28,
      "start_date": "1996-03",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2009-03-27",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870311"
    },
    {
      "nct_id": "NCT06544733",
      "title": "Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-Infection"
      ],
      "interventions": [
        {
          "name": "Lepetegravir",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir pacfosacil",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Match BVY",
          "type": "DRUG"
        },
        {
          "name": "Bictegravir/emtricitabine/tenofovir alafenamide",
          "type": "DRUG"
        },
        {
          "name": "Lepetegravir/Lenacapavir pacfosacil FDC",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Match GS1720/GS-4182 FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 675,
      "start_date": "2024-08-20",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544733"
    },
    {
      "nct_id": "NCT04177758",
      "title": "Evaluating Vitamin D3 Supplement on Post-Op Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Vitamin D",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-02-01",
      "completion_date": "2022-03-01",
      "has_results": true,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177758"
    },
    {
      "nct_id": "NCT06316843",
      "title": "Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "PASC Post Acute Sequelae of COVID 19"
      ],
      "interventions": [
        {
          "name": "Valacyclovir celecoxib dose 1",
          "type": "DRUG"
        },
        {
          "name": "Valacyclovir celecoxib dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bateman Horne Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 59,
      "start_date": "2023-10-15",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-22",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06316843"
    },
    {
      "nct_id": "NCT01656252",
      "title": "Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Phase I- Cytarabine & Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Phase II- Sequence A",
          "type": "DRUG"
        },
        {
          "name": "Phase II- Sequence B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-07",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2020-11-03",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 5,
      "location_summary": "Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01656252"
    },
    {
      "nct_id": "NCT01170338",
      "title": "Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Smoking",
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Varenicline 100 mg by mouth twice daily",
          "type": "DRUG"
        },
        {
          "name": "control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newark Beth Israel Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2008-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-07-27",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170338"
    },
    {
      "nct_id": "NCT07246863",
      "title": "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-Squamous Non-Small Cell Lung Cancer",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Visugromab RDE (recommended dose for expansion)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Visugromab 6mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Saline Infusion",
          "type": "OTHER"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2025-10-07",
      "completion_date": "2031-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-16T23:42:13.458Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07246863"
    }
  ]
}